Rachael Raw

Dr. Rachael Raw

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2021 in Expert Review of Medical Devices
Verified
Journal Article
Open access
Hilmar SigurdssonHilmar Sigurdsson
Hilmar Sigurdsson
RRRachael Raw
Rachael Raw
HHHeather Hunter
Heather Hunter
MBMark Baker
Mark Baker
JTJohn-Paul Taylor
John-Paul Taylor
AYAlison Yarnall
Alison Yarnall
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder with multifactorial etiology. While dopaminergic medication is the standard therapy in PD, it provides limited symptomati...

1 September 2021 in Journal of Infection
Verified
Journal Article
Closed access
RRRachael Raw
Rachael Raw
CKClive Anthony Kelly
Clive Anthony Kelly
JRJon Rees
Jon Rees
CWCaroline Wroe
Caroline Wroe
DCDavid Robert Chadwick
David Robert Chadwick

4 December 2021 in Vaccine
Verified
Journal Article
Closed access
RRRachael Raw
Rachael Raw
JRJon Rees
Jon Rees
CKClive A. Kelly
Clive A. Kelly
CWCaroline Wroe
Caroline Wroe
DCDavid R. Chadwick
David R. Chadwick

17 February 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
RRRachael Raw
Rachael Raw
JRJon Rees
Jon Rees
DCDavid R Chadwick
David R Chadwick
Prior studies suggest that adverse events (AEs) following doses one and two of BNT162b2/Pfizer vaccine are worse in those with a prior history of COVID-19. To establish whether this outcome applies to a third/booster dose, we conducted a survey with 534 healthcare workers (HCW) in Northeast England, who reported AEs following all three doses of BNT162b2/Pfizer vaccine. We also explored AEs associated with concurrent seasonal influenza immunisation, in a subset of 492 HCWs. For all doses of BNT162b2/Pfizer vaccine there was a cluster of systemic AEs that were consistently worse in HCWs with a prior history of COVID-19. AEs were no worse in HCWs who received their third/booster dose within 7 days of the influenza jab, rather than further apart. Gender and the presence of ongoing COVID-19 symptoms (OCS) had no effect on AEs associated with COVID-19 or influenza vaccination, though younger HCWs experienced more AEs overall. Our findings have implications for vaccine hesitancy and immunisation protocols.

22 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
RRRachael Raw
Rachael Raw
CKClive Kelly
Clive Kelly
JRJon Rees
Jon Rees
CWCaroline Wroe
Caroline Wroe
DCDavid R. Chadwick
David R. Chadwick
Importance: Understanding Adverse Events (AEs) associated with SARS-CoV-2 vaccination has public health implications, especially with regards to vaccine hesitancy. Objective: To establish whether individuals with prior history of COVID-19 were more likely to experience AEs after BNT162b2/Pfizer vaccination, than those without previous COVID-19, and whether COVID-19-vaccination interval influenced AE severity. Design: An observational study explored AEs after vaccination. Participants were invited to complete an electronic survey, capturing self-reported COVID-19 symptoms, PCR/antibody results, and AEs following first dose of BNT162b2/Pfizer vaccine. In a subset where PCR/antibody results could be verified, a sensitivity analysis was conducted. Setting: Three North-East England hospital Trusts in the United Kingdom. Participants: Healthcare workers formed an opportunistic sample – 265 of 974 reported prior positive SARS-CoV-2 PCR and/or antibody. Exposure: All participants had received their first dose of BNT162b2/Pfizer vaccine. Main Outcomes and Measures: Nature, severity, duration, and onset of self-reported AEs (reported via a modified version of the FDA Toxicity Grading Scale for vaccine-associated AEs), was compared between those with and without a prior history of COVID-19, using 2-way ANCOVA and logistic regression. Effects of age, gender, illness-vaccine interval, and ongoing symptoms (‘Long-COVID’) on AEs, were also explored. Results: Of 974 respondents (81% female, mean age 48), 265 (27%) reported previous COVID-19 infection. Within this group (symptoms median 8.9 months pre-vaccination), 30 (11%) complained of Long-COVID. The proportion reporting one moderate/severe symptom was higher in the previous COVID-19 group (56% v 47%, OR=1.5 [95%CI, 1.1–2.0], p=.009), with fever, fatigue, myalgia-arthralgia and lymphadenopathy significantly more common. There was no significant relationship between illness-vaccine interval and symptom composite score (r s =0.09, p=.44). Long-COVID was not associated with worse AEs in comparison to the group without previous COVID-19. In the smaller sensitivity analysis cohort (412 people) similar findings were obtained although only myalgia and arthralgia remained significant. Conclusions and Relevance: Prior COVID-19 infection but not ongoing Long-COVID symptoms were associated with an increase in the risk of self-reported adverse events following BNT162b2/Pfizer vaccination. COVID-19 illness-vaccination interval did not significantly influence AEs. This data can support education around vaccine-associated AEs and, through improved understanding, help to combat vaccine hesitancy. Key Points: Question: Does previous COVID-19 infection or ‘Long-COVID’ increase the frequency of Adverse Events (AEs) following first dose of BNT162b2/Pfizer vaccination? Findings: In a survey-based observational study, healthcare workers in the United Kingdom reported AEs experienced after their first dose of BNT162b2/Pfizer vaccine. Prior COVID-19 infection, but not Long-COVID, were associated with increased risk of self-reported AEs including lymphadenopathy post-vaccination. Duration since COVID-19 infection did not affect severity of AEs. Meaning: Our study can inform education and understanding of AEs associated with COVID-19 vaccination and help to combat vaccine hesitancy.

12 June 2023 in medRxiv
Verified
Preprint
Open access
PDF file
RRRachael Raw
Rachael Raw
JRJon Rees
Jon Rees
APAmy Pearson
Amy Pearson
DCDavid R. Chadwick
David R. Chadwick
Neurodivergent (ND) individuals (e.g., Autistic people) are more likely to experience health problems that are characterised by central sensitisation ’. Recent research suggests that a so-called ‘Long-COVID’ syndrome might also be explained by a heightened response to internal physiological stimuli, much like in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Using a standardised assessment tool, we examined whether traits associated with Autism would predict long-term COVID-19 symptoms in 267 Healthcare Workers (HCW).. Higher autistic traits predicted COVID-19 symptoms that lasting more than 12 weeks regardless of formal autism diagnosis. A personality measure also showed that negative affect was associated with experiencing COVID-19 symptoms for 4-12 weeks, though the direction of causality in this case is uncertain. Limitations of the present study are 1) the retrospective nature of COVID-19 symptom reporting; 2) likely self-selection bias given the high number of HCWs who reported long-term COVID-19 symptoms; and 3) the gender-bias towards females in our sample.